Transforming Computational Design Into Life Changing Medicines
iBio’s platform creates fully human antibodies with precision and function to become meaningful medicines. By optimizing both sides of the antibody-antigen equation, we accelerate discovery from target to therapeutic candidate.
From target to therapeutic candidate
Our platform uses three integrated technologies to deliver on-target, functional antibodies
Epitope-steering technology
Computational antigen design enables epitope-selective antibody discovery.
Mammalian display
Tailored high -dimensional selections in production cell lines identify developable antibodies translating to therapeutics. This process ensures we develop drug candidates with the specificity, developability, and functionality needed for clinical success.
Human-developable libraries
Antibodies engineered for manufacturability and low immunogenicity with StableHu™ AI
Why our approach works
Risk reduction
Epitope designs are experimentally validated before discovery begins. This is designed to reduce risk in the discovery process and prevents expensive failures from computational predictions that don’t translate to meaningful medical outcomes.
Function-first selection
We screen for therapeutic function (agonism, antagonism, modulation) early in the selection process. We can find functional clones faster than methods that screen for binding first and test function later.
Engineered for manufacturing
Our libraries are designed for stability, expression, and low aggregation risk. Therapeutic candidates move through development with less manufacturing issues that commonly stop programs late in the process.
Faster development cycles
Validating epitopes early and screening for function upfront is designed to reduce therapeutic candidates failing later in the development process. We move the right molecules to the clinic faster.
Structural insights
Rapid epitope mapping is made possible by measuring engineered epitope binding. In some cases, structure determination can be obtained from the antibody-epitope complex.
Tissue-selective targeting
Epitope-steering produces tissue-specific and receptor-selective antibodies in order to offer targeted treatment and limit unwanted effects.
Our platform in action
Discovery of selective antibodies against Amylin receptor, a high-value GPCR target for next-gen obesity therapeutics
Amylin Receptor: Next-gen obesity target
Generative AI antigen designs present the epitope of interest in a soluble format
High-throughput multidimensional FACS selects for hits with the desired specificity profile
Discovery of antibodies and nanobodies with exquisite amylin receptor specificity
Platform to pipeline
We’re building next-generation antibodies for transformative medicines.
Explore our pipeline
Partner with us
We work across disease areas and partnership models. Let’s discuss how we can accelerate and derisk your programs together.
partnership opportunities